Jaguar Health registers 40.9M shares for C/M Capital resale, flagging a potential 89% dilution overhang
JAGX is trading near its 52-week low of $0.95 (5.7% above the low) on elevated volume (1.8× avg).
Summary
Jaguar Health filed a prospectus for the resale of up to 40.9 million shares by C/M Capital under a $40 million equity line. If fully drawn, dilution could reach 89% of the current float, with shares sold at a discount to market.
Key Events · Financing and Capital Events · JAGX
-
40.9M Share Resale Registration
The prospectus registers up to 40,874,552 shares for resale by C/M Capital, consisting of 40M purchase shares and 874,552 commitment shares. If all shares were issued and outstanding, they would represent over 89% of the total shares outstanding.
-
Discounted Pricing Mechanics
The VWAP Purchase Price is set at 95% of the lowest of the VWAP during the purchase period, the lowest traded price over the prior five trading days, or the closing sale price on the purchase date—guaranteeing C/M Capital a discount on every draw.
-
Potential Proceeds and Dilution
The company may receive up to $40 million in gross proceeds from sales to C/M Capital. At the current stock price of ~$1.00, drawing the full $40 million would require issuing approximately 40 million shares, diluting existing holders by roughly 89%.
-
Commitment Shares Issued
As consideration for the equity line, C/M Capital receives $800,000 worth of common stock (257,898 shares already issued) plus a pre-funded warrant for 616,654 shares, adding immediate dilution.
Analysis · JAGX · Life Sciences
This prospectus activates the $40 million equity line with C/M Capital by registering 40.9 million shares for resale. At the current $1.00 stock price, existing holders would face roughly 89% dilution if all shares are issued. The shares are sold to C/M Capital at a discount—the VWAP purchase price is set at 95% of the lowest of several benchmarks—so the fund can immediately resell at a profit, creating persistent selling pressure. While the company controls the timing and amount of draws, the sheer size of the registered share block relative to the 4.9 million shares outstanding makes this a highly dilutive overhang. Proceeds are earmarked for working capital and redeeming Series P Preferred Stock, but the structure is classic death-spiral financing that could crush the stock if utilized aggressively.
At the time of this filing, JAGX was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.95 to $92.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.